Humacyte (HUMA) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Humacyte is facing substantial doubt regarding its ability to continue as a going concern through November 8, 2025, as outlined in its financial statement notes. The company’s survival hinges on generating positive cash flow, securing additional financing, forming strategic alliances, or selling assets. This precarious financial position may adversely impact its share price and ability to attract new capital or partnerships. In a worst-case scenario, liquidation of assets could yield returns significantly lower than current financial statement valuations.
The average HUMA stock price target is $13.00, implying 124.91% upside potential.
To learn more about Humacyte’s risk factors, click here.
